Skip to content
Search

Latest Stories

Dr June Raine appointed as chief of MHRA

The Medicines and Healthcare products Regulatory Agency’s (MHRA) has appointed Dr June Raine as its new chief executive, a position she was holding temporarily since 2019.

As head of the UK's medicines regulator, she is highly commended for playing a crucial part in ensuring the UK was the first in the world to authorise the Pfizer/BioNTech and Oxford University/AstraZeneca Covid-19 vaccines.


Health minister Lord Bethell said: “It is thanks to Dr Raine’s strong leadership during the pandemic that the UK was the first country in the world to authorise Covid-19 vaccines.

“The MHRA is widely regarded as one of the best regulators in the world with the highest standards of safety and I’m delighted to confirm Dr Raine’s appointment as CEO.

“I’m confident Dr Raine will build on MHRA’s success during the pandemic to make sure NHS patients are among the first to receive cutting-edge treatments in the future.”

Previous to becoming interim CEO, Dr Raine was director of Vigilance and Risk Management of Medicines and has worked for MHRA and its predecessor organisations for 36 years.

She qualified in medicine at the University of Oxford and undertook postgraduate research leading to an MSc in pharmacology and after several general medical posts, she joined the then Medicines Division of the Department of Health.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less